Imagion Biosystems (IBX), an ASX-listed company, is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Is advancing clinical development of its MagSense platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI.
ASX Code | IBX |
Website | http://www.imagionbiosystems.com |
Industry/Sector | Health Care Equipment |
Market Cap ($M) | 2 |
IBX Share Price | $0.074 |
Day High | $0.000 |
Day Low | $0.000 |
Last Close | $0.074 |
IBX Share Price Movement | - ( No change ) |
There are no dividends for Imagion Biosystems Limited (IBX). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
---|---|---|---|---|---|
Suspension from Quotation | 2 Apr 2024 9:38AM | $0.074 | $0.074 | $0.074 | fallen by 0% |
Appendix 4E and Preliminary Final Report | 29 Feb 2024 4:23PM | $0.091 | $0.074 | $0.074 | fallen by 18.68% |
Imagion Business Update | 28 Feb 2024 4:02PM | $0.084 | $0.074 | $0.074 | fallen by 11.90% |
See all ASX announcements from Imagion Biosystems Limited (IBX) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
---|---|---|---|---|---|---|---|
2023A | -$13.07 | -$42.90 | 22.50% | 0.00 | 0.00 | 0.00% | 0.0% |
2022A | -$9.81 | -$35.00 | 52.20% | 0.00 | 0.00 | 0.00% | 0.0% |
2021A | -$6.02 | -$23.00 | -23.10% | 0.00 | 0.00 | 0.00% | 0.0% |
Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | ||
Cochlear (COH) | $20,885M | 0.1063 | 0.3407 | 0.1157 | 68.8628 | 51.3643 | 46.0365 | 1.03% | 1.32% | 1.51% |
Fisher & Paykel Hlth (FPH) | $14,232M | -0.3337 | 0.0132 | 0.3117 | 60.5466 | 59.7597 | 45.5599 | 1.67% | 1.34% | 1.49% |
Imagion Biosystems (IBX) | $2M | 0.2249 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
ResMed (RMD) | $17,153M | 0.1879 | 0.0960 | 0.1090 | 29.9577 | 27.3348 | 24.6476 | 0.74% | 1.00% | 1.10% |
Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
---|---|---|---|---|
Company | 0.00 | 0.00 | -0.52 | 0.00 |
Market | 0.53 | 15.00 | 1.10 | 1.00 |
Sector | 0.84 | 33.00 | 2.36 | 2.40 |
Name | Position | Start Date |
---|---|---|
Mr Robert Romeo Proulx | Executive Director, Executive Chairman | 6 Dec 2016 |
Ms Dianne Margaret Angus | Non-Executive Director | 8 May 2020 |
Mr Michael (Mike) John Harsh | Non-Executive Director | 28 Feb 2017 |
Mr Mark Gerald Van Asten | Non-Executive Director | 6 Dec 2016 |
Mr David Gerald Ludvigson | Non-Executive Director | 8 Mar 2017 |
Ms Jovanka Naumoska | Non-Executive Director | 6 Dec 2016 |
Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
---|---|---|---|---|---|---|
21 Apr 2023 | VAN ASTEN, Mark | Issued | Direct Shares | 68,125 | $0.017 | $1,158.130 |
21 Apr 2023 | ANGUS, Dianne | Issued | Direct Shares | 30,375 | $0.017 | $516.377 |
21 Apr 2023 | ANGUS, Dianne | Issued | Direct Shares | 50,000 | $0.017 | $850.003 |
See all changes in directors' interest & trades for Imagion Biosystems Limited (IBX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
Name | Position |
---|---|
Yalia Jayalakshmi | Chief Development Officer |
Geoff Hollis | Chief Financial Officer,Company Secretary |
Date | Event |
---|---|
27 February 2025 | Report (Prelim) |
28 August 2024 | Report (Interim) |
Imagion Biosystems Limited's (IBX) current share price is $0.07. This constitutes a price movement of 0% when compared to the share price 7 days ago and is -81.73% below IBX's 12-month high of $0.41 per share. Prices are delayed by at least 20 minutes.
Relative to the previous close share price of $0.07, Imagion Biosystems Limited's (IBX) current share price of $0.07 constitutes a movement of or 0%. Imagion Biosystems Limited's (IBX) share price movement is 0% when compared to 7 days ago and is -81.73% below IBX's 52-week high of $0.41.
Imagion Biosystems Limited's (IBX) 52-week high is $0.41 which was reached on 7 Dec 2023. Relative to this, IBX's current share price of $0.07 constitutes a -$0.33 or -81.73% drop since that high of $0.41 per IBX share.
Imagion Biosystems Limited's (IBX) 52-week low is $0.01 which was reached on 10 Nov 2023. Relative to this, IBX's current share price of $0.07 constitutes a $0.06 or 640% gain since that low of $0.01 per IBX share.
Over the last 12 months, Imagion Biosystems Limited (IBX) has a daily average trading volume of 2,217,952 IBX shares per day.
Imagion Biosystems Limited (IBX) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for IBX is a ratio that tells you the percentage of Imagion Biosystems Limited's (IBX) share price that it pays out in dividends each year.
Imagion Biosystems Limited (IBX) will release its next Annual Report on n/a. Imagion Biosystems Limited's (IBX) last annual report was released on 28 Feb 2023. Click here to view Imagion Biosystems Limited's (IBX) last annual report.
Imagion Biosystems Limited (IBX) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
The price-to-earnings (P/E) ratio for Imagion Biosystems Limited (IBX) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Imagion Biosystems Limited's (IBX) share price to its earnings per IBX share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.